Overview

This trial is active, not recruiting.

Conditions helicobacter pylori, gastric antrum, corpus biopsies
Treatment endoscopic gastric biopsies from antrum and body
Sponsor Mansoura University
Start date June 2014
End date June 2016
Trial size 400 participants
Trial identifier NCT02675010, H1

Summary

There are controversies about the best sites -biopsy based -tests for H pylori associated gastritis. The study is designed to evaluate the optimal site of gastric mucosal biopsy for identification of Helicobacter pylori, especially in case of gastric atrophy and/or intestinal metaplasia.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose diagnostic
Arm
(Other)
ENDOSCOPIC BIOPSEIS TAKEN FROM BOTH ANTRUM AND CORPUS FOR H PYLORI DETECTION
endoscopic gastric biopsies from antrum and body
ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY

Primary Outcomes

Measure
H PYLORI POSITIVITY
time frame: 2 YEARS

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Patients included in this study are those with peptic ulcer disease, previous upper gastrointestinal surgery, a known or a suspected past history of H.pylori eradication therapy, a personal or first-degree family history of gastric cancer Exclusion Criteria: - those having received antibiotic or proton pump inhibitor treatment one month beforehand

Additional Information

Official title Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Multicenter Study
Description . The study is designed to evaluate the optimal site of gastric mucosal biopsy for identification of Helicobacter pylori, especially in case of gastric atrophy and/or intestinal metaplasia. 400 patients with dyspepsia are planned to be enrolled in this study. in addition to the routine antral biospy, corpus biospies are taken to evaluate the optimal site of gastric mucosal biopsy for identification of Helicobacter pylori, especially in case of gastric atrophy and/or intestinal metaplasia.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Mansoura University.